In anti-tumor applications, research has predominantly focused on well-validated targets such as CD19, CD20, and BCMA while in vivo CAR-T generation primarily employs lentiviral-based CAR gene delivery, with targeting strategies involving CD3, CD8, CD7, and anti-TCR nanobody. Here, CD19 is linked to neoplasm.